ALT - Altimmune Inc
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
24%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -46.57%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative but improving
Net Margin is -2432.9%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 11.41
Debt Ratio is 0.12
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.01
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Altimmune Inc (ALT) - www.altimmune.com
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Vipin Garg
Employees - 43
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.